{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:25:14Z","timestamp":1791321914230,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia and by Slovenian Research Agency","award":["P1-0189"],"award-info":[{"award-number":["P1-0189"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejpb.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T01:54:52Z","timestamp":1571450092000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Suitability of RPMI 2650 cell models for nasal drug permeability prediction"],"prefix":"10.1016","volume":"145","author":[{"given":"Nadica","family":"Sibinovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"\u017dakelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Kristan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.10.008_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2013possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2019.10.008_b0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.10.008_b0015","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2019.10.008_b0020","series-title":"Drug Absorption Studies: In Situ, In Vitro and In Silico Models","first-page":"216","article-title":"In Vitro Cellular Models for Nasal Drug Absorption Studies","author":"Kim","year":"2008"},{"key":"10.1016\/j.ejpb.2019.10.008_b0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejpb.2009.08.008","article-title":"RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies","volume":"74","author":"Wengst","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tiv.2004.07.003","article-title":"The use of human nasal in vitro cell systems during drug discovery and development","volume":"19","author":"Dimova","year":"2005","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2019.10.008_b0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","article-title":"Preclinical experimental models of drug metabolism and disposition in drug discovery and development","volume":"2","author":"Zhang","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2019.10.008_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13318-017-0426-x","article-title":"Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?","volume":"43","author":"Mercier","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2019.10.008_b0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejps.2018.07.040","article-title":"Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells","volume":"123","author":"Dolberg","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.10.008_b0050","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1023\/A:1026112107100","article-title":"Serially passaged human nasal epithelial cell monolayer for in vitro drug transport studies","volume":"20","author":"Yoo","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11095-014-1494-0","article-title":"The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model","volume":"32","author":"Kreft","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/1097-0142(196402)17:2<170::AID-CNCR2820170206>3.0.CO;2-N","article-title":"Studies of a human tumor cell line with a diploid karyotype","volume":"17","author":"Moore","year":"1964","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2019.10.008_b0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0014-4827(65)90022-4","article-title":"Human tumor cell line with a quasi-diploid karyotype (RPMI 2650)","volume":"39","author":"Moorhead","year":"1965","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0070","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jps.21031","article-title":"Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies","volume":"97","author":"Bai","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.10.008_b0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2016.05.010","article-title":"Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells","volume":"508","author":"Dolberg","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10616-012-9493-7","article-title":"Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability","volume":"65","author":"Kurti","year":"2013","journal-title":"Cytotechnology"},{"key":"10.1016\/j.ejpb.2019.10.008_b0085","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.2042-7158.2012.01540.x","article-title":"Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions","volume":"64","author":"Reichl","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2019.10.008_b0090","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1021\/acs.molpharmaceut.6b00838","article-title":"Activity of multidrug resistance-associated proteins 1\u20135 (MRP1-5) in the RPMI 2650 cell line and explants of human nasal turbinate","volume":"14","author":"Dolberg","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0095","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.molpharmaceut.8b00087","article-title":"Pharmacological characterization of the RPMI 2650 model as a relevant tool for assessing the permeability of intranasal drugs","volume":"15","author":"Mercier","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0100","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1007\/s11095-017-2251-y","article-title":"A Comparison of drug transport in pulmonary absorption models: isolated perfused rat lungs, respiratory epithelial cell lines and primary cell culture","volume":"34","author":"Bosquillon","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0105","unstructured":"FDA U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry, December 2017. https:\/\/www.fda.gov\/media\/70963\/download, 2017 (accessed 07 January 2019)."},{"key":"10.1016\/j.ejpb.2019.10.008_b0110","unstructured":"European Medicines Agency, ICH guideline M9 on biopharmaceutics classification system based biowaivers Step 2b, 2018."},{"key":"10.1016\/j.ejpb.2019.10.008_b0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/jphp.13111","article-title":"Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines","volume":"71","author":"Jarc","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2019.10.008_b0120","unstructured":"Center for drug evaluation and research. Application number: 200796Orig1s000 Pharmacology review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/200796Orig1s000PharmR.pdf, 2010 (accessed 2 July 2019)."},{"key":"10.1016\/j.ejpb.2019.10.008_b0125","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/jps.23027","article-title":"Suitability of isolated rat jejunum model for demonstration of complete absorption in humans for BCS-based biowaiver request","volume":"101","author":"Peternel","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.10.008_b0130","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2019.10.008_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.ejpb.2019.10.008_b0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-5173(94)90200-3","article-title":"In vitro permeation of several model drugs across rabbit nasal mucosa","volume":"103","author":"Kubo","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0145","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1208\/s12248-010-9227-8","article-title":"Application of method suitability for drug permeability classification","volume":"12","author":"Volpe","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.10.008_b0150","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1021\/acs.molpharmaceut.5b00103","article-title":"Microarray determination of the expression of drug transporters in humans and animal species used for the investigation of nasal absorption","volume":"12","author":"Al-Ghabeish","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0155","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2019.10.008_b0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.2042-7158.2010.01221.x","article-title":"Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal drug transport study","volume":"63","author":"Cho","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2019.10.008_b0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejpb.2019.04.002","article-title":"Pharmacological characterization of the 3D MucilAir nasal model","volume":"139","author":"Mercier","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update","volume":"17","author":"Mao","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.10.008_b0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejpb.2016.07.010","article-title":"Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products","volume":"107","author":"Pozzoli","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2133\/dmpk.DMPK-11-NT-068","article-title":"ABCG2 modulates chlorothiazide permeability\u2013in vitro-characterization of its interactions","volume":"27","author":"Beery","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2019.10.008_b0185","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/mp4007858","article-title":"Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery","volume":"11","author":"Larregieu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0190","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/mp500152y","article-title":"The low\/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol","volume":"11","author":"Zur","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13318-012-0094-9","article-title":"Transepithelial transport of rosuvastatin and effect of ursolic acid on its transport in Caco-2 monolayers","volume":"37","author":"Hua","year":"2012","journal-title":"Eur. J Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2019.10.008_b0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1018814627484","article-title":"Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+\/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux","volume":"16","author":"Bretschneider","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0205","doi-asserted-by":"crossref","first-page":"25672","DOI":"10.1074\/jbc.270.43.25672","article-title":"Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2","volume":"270","author":"Ganapathy","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2019.10.008_b0210","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1021\/mp100234z","article-title":"Proton-coupled oligopeptide transporter (POT) family expression in human nasal epithelium and their drug transport potential","volume":"8","author":"Agu","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0215","unstructured":"H.-J. Cho, U. Termsarasab, J. Kim, D.-D. Kim, In Vitro Nasal Cell Culture Systems for Drug Transport Studies, 2010."},{"key":"10.1016\/j.ejpb.2019.10.008_b0220","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1023\/A:1016038119909","article-title":"In-vitro cell culture models of the nasal epithelium: a comparative histochemical investigation of their suitability for drug transport studies","volume":"13","author":"Werner","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.10.008_b0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.ejpb.2019.10.008_b0230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/aivt.2017.0035","article-title":"Establishment of a human 3D tissue-based assay for upper respiratory tract absorption","volume":"4","author":"Hoffmann","year":"2018","journal-title":"Appl. In Vitro Toxicol."},{"key":"10.1016\/j.ejpb.2019.10.008_b0235","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/jps.24489","article-title":"The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail","volume":"104","author":"Ebner","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.10.008_b0240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/pharmaceutics11080367","article-title":"Improved in vitro model for intranasal mucosal drug delivery: primary olfactory and respiratory epithelial cells compared with the permanent nasal cell line RPMI 2650","volume":"11","author":"Ladel","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2019.10.008_b0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2019.10.008_b0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0260","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/bdd.751","article-title":"Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue","volume":"32","author":"Haslam","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2019.10.008_b0265","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional intestinal permeability in rats: a comparison of methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.10.008_b0270","series-title":"Suitability of Rosuvastatin as a Specifid Marker OG ABCG2 Transporter Activity in Mucous Membrane of the Rat Small Intestine","first-page":"58","author":"Miona","year":"2016"},{"key":"10.1016\/j.ejpb.2019.10.008_b0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/bdd.366","article-title":"Comparison of ceftibuten transport across Caco-2 cells and rat jejunum mounted on modified ussing chambers","volume":"24","author":"Menon","year":"2003","journal-title":"Biopharm. Drug Dispos."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119308732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119308732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:35:31Z","timestamp":1760546131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119308732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":55,"alternative-id":["S0939641119308732"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.10.008","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suitability of RPMI 2650 cell models for nasal drug permeability prediction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}